Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2026)
31 slides from Starpharma's shareholder meeting presentation, Nov 6, 2026
Slide 1: AGM Chair address and CEO presentation
ASX Announcement For personal use only AGM Chair address and CEO presentation Melbourne, Australia; 6 November 2026: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company advancing dendrimer technology from the lab to the patient, today provides a copy of the Chair’s address and
Slide 2: Chair's address to shareholders
Starpharma Holdings Limited Annual General Meeting For personal use only 6 November 2026 Chair’s address to shareholders Welcome Good afternoon, fellow shareholders. Welcome to Starpharma’s 2026 Annual General Meeting. On behalf of the Board, thank you for joining us and for your continued support o
Slide 3: Strategic partnerships and external validation
We are encouraged by the preclinical results to date. We are also encouraged by feedback from key opinion leaders and clinicians. For personal use only Together, this gives us confidence that we are progressing a differentiated product candidate which can add real value. The program represents an im
Slide 4: Chair's address: team and culture
Our partners consistently recognise the team’s expertise, responsiveness and collaborative approach. For personal use only And we remain focused on recruiting the right capabilities, strengthening a culture of collaboration and accountability, and building high-performing teams. This is essential as
Slide 5: Starpharma Holdings Limited Annual General Meeting
rsonal use only Starpharma Holdings Limited (ASX:SPL) (US OTC:SPHRY) Annual General Meeting 6 November 2026 I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6
Slide 6: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements rsonal use only This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance th
Slide 7: Our Mission and Purpose
Our Mission and Purpose Redefining cancer treatment with dendrimer science rsonal use only Our mission Help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology. ANNUAL GENERAL MEETING 202
Slide 8: The Road to the Patient
The Road to the Patient A complex journey that requires many connected steps, different areas of expertise, and a shared commitment to patients rsonal use only ANNUAL GENERAL MEETING 2026 4
Slide 9: 2025-26 Operational Highlights
2025-26 Operational Highlights Significant progress across the DEP® platform, strategic partnerships and radiotheranostics pipeline rsonal use only Strategic validation & partnering Research & development Sustainable operations Genentech Strategic collaboration & licence DEP® HER2-Lutetium Commercia
Slide 10: From Broad Platform Validation to Focused Oncology Value Creation
From Broad Platform Validation to Focused Oncology Value Creation Two decades of dendrimer expertise are now being concentrated on high-value targeted oncology opportunities rsonal use only FROM TO Building and validating a versatile A focused targeted oncology company dendrimer platform Applying DE
Slide 11: Two Complementary DEP Approaches to Drive Shareholder Value
Two Complementary DEP® Approaches to Drive Shareholder Value Building value through proprietary assets and strategic partnerships rsonal use only OWN AND ADVANCE Build differentiated DEP® oncology assets in selected high Proprietary value therapeutic areas. assets VALUE: asset ownership • partnering
Slide 12: Evolving Asset Pipeline
Evolving Asset Pipeline Strategic focus on targeted therapies and partnerships in oncology to drive shareholder value rsonal use only Target Pre- Product Phase 1 Phase 2 Phase 3 Status Partner Pipeline Indication clinical Combined $1B+ deal value Targeted Therapies HER2+ cancers, DEP® HER2-Lutetium
Slide 13: Disciplined Discovery Pipeline of Proprietary DEP Assets
Disciplined Discovery Pipeline of Proprietary DEP® Assets Focusing capital where patient need, platform advantage and value potential align rsonal use only HIGH UNMET NEED CLEAR DEP® ADVANTAGE ATTRACTIVE VALUE POTENTIAL Meaningful patient need and scope A defined role for DEP® in improving Strong sc
Slide 14: DEP HER2-Lu – Targeted Radioligand Therapy Leveraging Dendrimer Technology
DEP® HER2-Lu – Targeted Radioligand Therapy Leveraging Dendrimer Technology Differentiated profile with potential to enhance tumour targeting and tolerability rsonal use only First-in-class HER2 Radiotherapy DEP® HER2-lutetium Optimised Design: Parameter Target Product Profile DEP® HER2-lutetium Sch
Slide 15: DEP HER2-Lu Program Status
DEP® HER2-Lu Program Status First-in-human Phase 1 study to commence in December 2026 subject to ethics approval Regulatory milestones Clinical manufacturing Site preparations rsonal use only FDA type C meeting complete; ethics Inhouse manufacture and Radiopharmacy set-up Operational start-up toward
Slide 16: DEP HER2-Lutetium Achieves Strong Uptake & Retention in HER2+ Tumours
DEP® HER2-Lutetium Achieves Strong Uptake & Retention in HER2+ Tumours Strong tumour uptake and prolonged tumour retention with low kidney exposure DEP® HER2-Lu vs. radiolabelled HER2-targeting VHH without dendrimer, HER2-VHH-Lu rsonal use only 4 hours 48 hours 5 days 12 days HER2-VHH-Lu DEP® HER2-L
Slide 17: DEP HER2-Lutetium Achieves Strong Uptake & Retention in HER2+ Tumours
DEP® HER2-Lutetium Achieves Strong Uptake & Retention in HER2+ Tumours Fast blood clearance, minimal kidney exposure and favourable tumour to tissue ratios DEP® HER2-Lu Blood Clearance rsonal use only 50 Fast clearance from blood DEP® HER2-Lu Biodistribution Radioactivity (%ID/g) 40 30 35 20 48 hour
Slide 18: DEP HER2-Lutetium Achieves Significant Anti-tumour Activity & Survival Benefits
DEP® HER2-Lutetium Achieves Significant Anti-tumour Activity & Survival Benefits Durable tumour growth control and survival benefits that are comparable to Enhertu® HER2-positive (high-expressing) cancer model; DEP® HER2-Lu (25 MBq) and DEP® HER2-Lu (15 MBq) vs. Enhertu®, HER2-VHH-Lu and Vehicle rso
Slide 19: DEP HER2-Lu Clinical Development Strategy
DEP® HER2-Lu Clinical Development Strategy Significant unmet need offers potential for Accelerated Approval H2 CY27 rsonal use only H2 CY26 Topline readout for up to 15 CY28 Study to commence following Phase 2/3 ready POTENTIAL FOR ACCELERATED APPROVAL patients from FIH/Ph 1 ethics approval Ph 1/2 (
Slide 20: DEP Benefits Extend Across Radioligand Targets
DEP® Benefits Extend Across Radioligand Targets Focused preclinical work in HER2, PSMA and EGFR to show the dendrimer advantage is not target-specific rsonal use only Consistent tumour uptake across HER2-, PSMA- and EGFR-targeted DEP® constructs HER2 Consistent DEP® profile across different tumour t
Slide 21: Partnering and Business Development
Partnering and Business Development Converting DEP® technology into partner-funded value across oncology and radiotheranostics Partnering Strategy rsonal use only Out-license and co-develop DEP® assets with partners who fund development. Starpharma generates value through milestones, royalties and,
Slide 22: Petalion: Greater Ownership, Greater Value
Petalion: Greater Ownership, Greater Value Stake up from 22.5% to 66%, advancing a FAP-targeted DEP® oncology program rsonal use only Important Strategic Step WHY IT MATTERS FOR STARPHARMA VALUE FOR SHAREHOLDERS FAP Portfolio: adds a FAP-targeted dendrimer-drug Greater share of upside: 66% ownership
Slide 23: FAP: A High-Value Target with a Clear 12-Month Path
FAP: A High-Value Target with a Clear 12-Month Path DEP® delivery aims to turn a validated stromal target into an IND-ready lead rsonal use only 1 Why FAP matters 2 The delivery challenge 3 How DEP® helps • Pan-cancer stromal target: • Remain stable in circulation • Designed to improve stromal pancr
Slide 24: Genentech Collaboration and License Agreement
Genentech Collaboration and License Agreement Collaboration overview, financial terms and strategic significance Collaboration Overview About Genentech rsonal use only Starpharma employing its proprietary DEP® platform technology to develop dendrimer- drug conjugates that incorporate Genentech medic
Slide 25: Marketed Consumer Health Products
Marketed Consumer Health Products Supporting revenue through partner-led commercialisation, market expansion and digital marketing VivaGel® BV Viraleze rsonal use only Non-antibiotic gel for treatment of bacterial vaginosis (BV) and Broad-spectrum topical antiviral nasal spray prevention of recurren
Slide 26: Putting AI to Work at Starpharma
Putting AI to Work at Starpharma Targeted adoption that accelerates science and enables our people to perform at their best rsonal use only Faster research and Leaner everyday operations Adopted only where it adds development value Drafting, summarising, reporting and routine AI-assisted data analys
Slide 27: Great Place to Work Certified & Top Ranking
Great Place to Work® Certified & Top 10 Ranking A positive, inclusive and high-trust culture rsonal use only Great Place To Work® Australia’s 2026 Best Workplaces in #7 Biotechnology and Pharmaceuticals 1. Sandoz Australia and New Zealand 6. AMSL Diabetes Best Workplaces in 2. Servier Australia 7. S
Slide 28: Financial Summary
Financial Summary Well placed to execute our strategy A$37.9m rsonal use only Pro forma cash balance SPL share price At 30 September 2026, including the $3.5m R&D tax incentive A$30m Net proceeds raised Fully underwritten Entitlement Offer 11 August 2026 A$220m Current market cap Market capitalisati
Slide 29: Focusing on Strategic Execution and Revenue Generation
Focusing on Strategic Execution and Revenue Generation Important catalysts we are working towards in the next 12-18 months rsonal use only 1H CY27 2H CY27 1H CY28 DEP® HER2 Program DEP® HER2 Program • Initial data readout from ~3-4 patients • Ph 1/2 continuation DEP® HER2 Program from FIH / Ph 1 stu
Slide 30: Board & Leadership Team
Board & Leadership Team Driving innovation with global expertise rsonal use only Rob Thomas AO Cheryl Maley Dr Russell Basser David McIntyre Lynda Cheng Dr Jeff Davies Justin Cahill Independent Chief Executive Independent Independent Non-Executive Independent Independent Chief Financial & Non-Execut
Slide 31: Thank you
rsonal use only Thank you Investor Relations Corporate Office Investor.Relations@Starpharma.com Level 3, 40 River Boulevard www.Starpharma.com Richmond, Victoria 3121 Australia I N V E S T O R P R E S E N T A T I O N M A Y 2 0 2 6
Starpharma Holdings — Shareholder Meeting (November 2026) on 6ix